EMBC
Embecta·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
High Cash/net Profit Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EMBC
Embecta Corp.
One of the largest pure-play diabetes management companies in the world
Healthcare Equipment and Supplies
07/08/2021
04/01/2022
NASDAQ Stock Exchange
1,850
09-30
Common stock
300 Kimball Drive
Suite 300
Parsippany
New Jersey 07054
--
Embecta Corp. was incorporated in Delaware on July 8, 2021. The company is a leading global medical device company focused on providing solutions to improve the health and well-being of people with diabetes. On a century-old basis, the company believes that its products have become one of the most widely recognized and respected brands in the field of diabetes management in the world. The company estimates that its products are used by more than 30 million people in more than 100 countries for the daily management of insulin and diabetes. The company has a broad portfolio of marketed products, including a variety of pen needles, syringes and safety devices, supplemented by proprietary digital applications designed to help people manage diabetes.
Earnings Call
Company Financials
EPS
EMBC has released its 2025 Q4 earnings. EPS was reported at 0.5, versus the expected 0.46, beating expectations. The chart below visualizes how EMBC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EMBC has released its 2025 Q4 earnings report, with revenue of 264.00M, reflecting a YoY change of -7.72%, and net profit of 26.40M, showing a YoY change of 80.82%. The Sankey diagram below clearly presents EMBC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available



